The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.
Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.
The products combine next-generation sequencing and analysis with the company's NGSengine software to provide high-resolution HLA genotyping information.
As the life science industry left 2020 behind, it joined a new trend: going public through a mechanism that combines an IPO and merger in one transaction.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.
The cell analysis firm beat the consensus top line Wall Street estimates for Q4 and full-year 2020, but missed on the bottom line for the year.
GenMark said its ePlex molecular diagnostic product revenue for Q4 was $45.4 million, an increase of 138 percent over the fourth quarter of 2019.
The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.
The researchers focused particularly on genes whose expression changed in the hippocampus of people with Alzheimer's disease.